These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

632 related articles for article (PubMed ID: 28130206)

  • 1. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study.
    van der Heijde D; Deodhar A; Wei JC; Drescher E; Fleishaker D; Hendrikx T; Li D; Menon S; Kanik KS
    Ann Rheum Dis; 2017 Aug; 76(8):1340-1347. PubMed ID: 28130206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patients.
    Maksymowych WP; van der Heijde D; Baraliakos X; Deodhar A; Sherlock SP; Li D; Fleishaker D; Hendrikx T; Kanik KS
    Rheumatology (Oxford); 2018 Aug; 57(8):1390-1399. PubMed ID: 29718421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials.
    Panés J; Sandborn WJ; Schreiber S; Sands BE; Vermeire S; D'Haens G; Panaccione R; Higgins PDR; Colombel JF; Feagan BG; Chan G; Moscariello M; Wang W; Niezychowski W; Marren A; Healey P; Maller E
    Gut; 2017 Jun; 66(6):1049-1059. PubMed ID: 28209624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study.
    Deodhar A; Sliwinska-Stanczyk P; Xu H; Baraliakos X; Gensler LS; Fleishaker D; Wang L; Wu J; Menon S; Wang C; Dina O; Fallon L; Kanik KS; van der Heijde D
    Ann Rheum Dis; 2021 Aug; 80(8):1004-1013. PubMed ID: 33906853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials.
    Papp KA; Menter MA; Abe M; Elewski B; Feldman SR; Gottlieb AB; Langley R; Luger T; Thaci D; Buonanno M; Gupta P; Proulx J; Lan S; Wolk R;
    Br J Dermatol; 2015 Oct; 173(4):949-61. PubMed ID: 26149717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial.
    Papp KA; Bissonnette R; Gooderham M; Feldman SR; Iversen L; Soung J; Draelos Z; Mamolo C; Purohit V; Wang C; Ports WC
    BMC Dermatol; 2016 Oct; 16(1):15. PubMed ID: 27716172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study.
    Tanaka Y; Takeuchi T; Yamanaka H; Nakamura H; Toyoizumi S; Zwillich S
    Mod Rheumatol; 2015 Jul; 25(4):514-21. PubMed ID: 25496464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study.
    McInnes IB; Kim HY; Lee SH; Mandel D; Song YW; Connell CA; Luo Z; Brosnan MJ; Zuckerman A; Zwillich SH; Bradley JD
    Ann Rheum Dis; 2014 Jan; 73(1):124-31. PubMed ID: 23482473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
    Bachelez H; van de Kerkhof PC; Strohal R; Kubanov A; Valenzuela F; Lee JH; Yakusevich V; Chimenti S; Papacharalambous J; Proulx J; Gupta P; Tan H; Tawadrous M; Valdez H; Wolk R;
    Lancet; 2015 Aug; 386(9993):552-61. PubMed ID: 26051365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.
    Ogdie A; de Vlam K; McInnes IB; Mease PJ; Baer P; Lukic T; Gruben D; Kwok K; Wang C; Hsu MA; Maniccia A
    RMD Open; 2020 Feb; 6(1):. PubMed ID: 32396519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.
    Burmester GR; Blanco R; Charles-Schoeman C; Wollenhaupt J; Zerbini C; Benda B; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Soma K; Bradley J; Mebus C;
    Lancet; 2013 Feb; 381(9865):451-60. PubMed ID: 23294500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study.
    Papp KA; Krueger JG; Feldman SR; Langley RG; Thaci D; Torii H; Tyring S; Wolk R; Gardner A; Mebus C; Tan H; Luo Y; Gupta P; Mallbris L; Tatulych S
    J Am Acad Dermatol; 2016 May; 74(5):841-50. PubMed ID: 26899199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time to improvement of pain, morning stiffness, fatigue, and disease activity in patients with ankylosing spondylitis treated with tofacitinib: a post hoc analysis.
    Navarro-Compán V; Deodhar A; Bahiri R; Bushmakin AG; Cappelleri JC; Rammaoui J
    Arthritis Res Ther; 2024 May; 26(1):105. PubMed ID: 38790040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tofacitinib with conventional synthetic disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: Patient-reported outcomes from a Phase 3 randomized controlled trial.
    Li Z; An Y; Su H; Li X; Xu J; Zheng Y; Li G; Kwok K; Wang L; Wu Q
    Int J Rheum Dis; 2018 Feb; 21(2):402-414. PubMed ID: 29314645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.
    Mease P; Hall S; FitzGerald O; van der Heijde D; Merola JF; Avila-Zapata F; Cieślak D; Graham D; Wang C; Menon S; Hendrikx T; Kanik KS
    N Engl J Med; 2017 Oct; 377(16):1537-1550. PubMed ID: 29045212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial.
    Navarro-Compán V; Wei JC; Van den Bosch F; Magrey M; Wang L; Fleishaker D; Cappelleri JC; Wang C; Wu J; Dina O; Fallon L; Strand V
    RMD Open; 2022 Jun; 8(2):. PubMed ID: 35654457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Tofacitinib in Ankylosing Spondylitis by Baseline C-Reactive Protein Level: Post Hoc Analysis of Phase II and Phase III Clinical Trials.
    Deodhar A; Baraliakos X; Magrey M; Gensler LS; Thorat AV; Pemmaraju SK; Cadatal MJ; Nash P
    J Rheumatol; 2024 Aug; 51(8):772-780. PubMed ID: 38825359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.
    Papp KA; Menter A; Strober B; Langley RG; Buonanno M; Wolk R; Gupta P; Krishnaswami S; Tan H; Harness JA
    Br J Dermatol; 2012 Sep; 167(3):668-77. PubMed ID: 22924949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exposure-response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose-ranging phase 2 trial.
    Mukherjee A; Hazra A; Smith MK; Martin SW; Mould DR; Su C; Niezychowski W
    Br J Clin Pharmacol; 2018 Jun; 84(6):1136-1145. PubMed ID: 29377257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone.
    Kremer JM; Cohen S; Wilkinson BE; Connell CA; French JL; Gomez-Reino J; Gruben D; Kanik KS; Krishnaswami S; Pascual-Ramos V; Wallenstein G; Zwillich SH
    Arthritis Rheum; 2012 Apr; 64(4):970-81. PubMed ID: 22006202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.